Sun Pharma bought FDA-troubled Ranbaxy for $4 billion and fixed it

In April 2014 Sun Pharma's Dilip Shanghvi agreed to buy troubled rival Ranbaxy in a $4 billion all-stock transaction, including $800 million of debt. Ranbaxy was under US FDA import alerts at several plants after a 2013 settlement in which it pleaded guilty to producing adulterated drugs and paid $500 million.

The merger was consummated on March 25, 2015, after approvals including the Competition Commission's conditional nod with a divestment of seven brands. The combined company became India's largest and the world's fifth-largest drugmaker.

Sun's bet was that it could do what it had done with its own troubled plants: rehabilitate manufacturing, clear FDA bans and restart US supply. In March 2017 the FDA lifted the import alert on Ranbaxy's Mohali plant — under the ban since 2013 — clearing the path for approved products to reach the US market.

Financially the merger scaled the group: by FY20 India sales were ₹9,710 crore, about 30 per cent of revenue, US sales were $1,487 million, and full-year net profit rose 41 per cent to ₹3,764.93 crore on revenue of ₹32,837.5 crore.

The merger made Sun India's largest and the world's fifth-largest drugmaker; the FDA lifted the Mohali import alert in 2017; FY20 net profit rose 41% to ₹3,765 crore.

Sun's own turnaround of Caraco plants showed it could rehabilitate FDA-troubled facilities, making Ranbaxy a repair job rather than a leap of faith.

An all-stock deal preserved cash for the multi-year plant remediation and integration Ranbaxy required.

The merger scale — India's largest, world's fifth-largest drugmaker — gave Sun distribution and R&D leverage its rivals lacked.

Regulatory progress was concrete: the Mohali import alert was lifted in March 2017, reopening US supply from a formerly Ranbaxy plant.

A distressed rival is worth buying when you have the repair capability others lack: Sun had rehabilitated its own FDA-banned Caraco plants, so Ranbaxy was a fixable problem, not a gamble.

Sun spent 2015-16 integrating Ranbaxy and working through its FDA legacy, and the Mohali clearance in 2017 was the first big regulatory win; other former Ranbaxy sites, such as Halol, kept the cleanup going. Revenue from operations reached ₹32,837.5 crore in FY20 with net profit up 41 per cent, and Sun remained India's largest drugmaker. The acquisition's long shadow was the continuing FDA scrutiny, but the company's scale and specialty pipeline (Ilumya) sustained its market leadership.